Dokument: New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma
| Titel: | New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma | |||||||
| URL für Lesezeichen: | https://docserv.uni-duesseldorf.de/servlets/DocumentServlet?id=67955 | |||||||
| URN (NBN): | urn:nbn:de:hbz:061-20241212-094602-7 | |||||||
| Kollektion: | Publikationen | |||||||
| Sprache: | Englisch | |||||||
| Dokumententyp: | Wissenschaftliche Texte » Artikel, Aufsatz | |||||||
| Medientyp: | Text | |||||||
| Autoren: | Meneceur, Sarah [Autor] de Vos, Caroline Evelyn [Autor] Petzsch, Patrick [Autor] Köhrer, Karl [Autor] Niegisch, Günter [Autor] Hoffmann, Michéle Janine [Autor] | |||||||
| Dateien: |
| |||||||
| Stichwörter: | HDACi, cisplatin, bladder cancer, quisinostat, talazoparib | |||||||
| Beschreibung: | Urothelial carcinoma (UC) urgently requires new therapeutic options. Histone deacetylases (HDAC) are frequently dysregulated in UC and constitute interesting targets for the development of alternative therapy options. Thus, we investigated the effect of the second generation HDAC inhibitor (HDACi) quisinostat in five UC cell lines (UCC) and two normal control cell lines in comparison to romidepsin, a well character-
ized HDACi which was previously shown to induce cell death and cell cycle arrest. In UCC, quisinostat led to cell cycle alterations, cell death induction and DNA damage, but was well tolerated by normal cells. Combinations of quisinostat with cisplatin or the PARP inhibitor talazoparib led to decrease in cell viability and significant synergistic effect in five UCCs and platinum-resistant sublines allowing dose reduction. Further analyses in UM-UC-3 and J82 at low dose ratio revealed that the mechanisms included cell cycle disturbance, apoptosis induction and DNA damage. These combinations appeared to be well tolerated in normal cells. In conclusion, our results suggest new promising combination regimes for treatment of UC, also in the cisplatin resistant setting. | |||||||
| Rechtliche Vermerke: | Originalveröffentlichung:
Meneceur, S., de Vos, C. E., Petzsch, P., Köhrer, K., Niegisch, G., & Hoffmann, M. J. (2024). New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma. Journal of Cellular and Molecular Medicine, 28(9), Article e18342. https://doi.org/10.1111/jcmm.18342 | |||||||
| Lizenz: |  Dieses Werk ist lizenziert unter einer Creative Commons Namensnennung 4.0 International Lizenz | |||||||
| Fachbereich / Einrichtung: | Medizinische Fakultät | |||||||
| Dokument erstellt am: | 12.12.2024 | |||||||
| Dateien geändert am: | 12.12.2024 |
